Skip to main content
Watch Insiders
DMRASector not reported

Damora Therapeutics, Inc. (DMRA) Insider Trading

In the last 90 days, 1 Damora Therapeutics, Inc. (DMRA) insider reported 1 open-market purchase totaling $252,875 and no sales. The most recent open-market purchase was reported on Sep 25, 2026. Source: SEC Form 4 filings.

SEC-reported filing activity is provided for research purposes and is not investment advice.

90-day C-suite buyers
1
90-day purchase value
$252,875
Corporate buyers
1
Latest transaction
Sep 25, 2026

Executive filings

Open-market transaction history

Purchase and sale summaries are ordered by the latest reported transaction date.

Open-market insider purchase and sale transactions
DateInsider nameRoleTypeSharesPriceTotal value
Sep 25, 2026Jennifer JarrettDirector, President and CEOOpen Market Purchase12,500$20.23$252,875
Jul 6, 2026Garrett WinslowGeneral CounselSale245$29.98$7,345

Common questions

DMRA insider trading FAQ

Are DMRA insiders buying or selling?
Over the last 90 days, DMRA insiders were net buyers, reporting $252,875 of open-market purchases and $0.00 of sales.
When was the last DMRA insider purchase?
The most recent open-market purchase of Damora Therapeutics, Inc. stock by an insider was reported on Sep 25, 2026, one of 1 purchase in the last 90 days.
Where does DMRA insider trading data come from?
Watch Insiders reads the SEC Form 4 filings that Damora Therapeutics, Inc. officers, directors, and 10% owners submit to EDGAR, and refreshes this page daily.